Once-Weekly Subcutaneous Semaglutide Improves Fatty Liver Disease in Patients with Type 2 Diabetes: A 52-Week Prospective Real-Life Study
Open accessThe DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.
Abstract
Background. Nonalcoholic fatty liver disease (NAFLD) is commonly observed in patients with type 2 diabetes (T2D). Semaglutide, a glucagon-like peptide 1 receptor agonist, may have a therapeutic role by targeting common mechanisms involved in the pathophysiology of T2D and NAFLD. The study aimed to assess the effectiveness of Semaglutide on NAFLD in patients with T2D. Methods. Forty-eight patients were treated with subcutaneous Semaglutide in add-on to metformin for 52 weeks. After the baseline visit (T0), follow-up was scheduled quarterly (T3, and T6) and then at 12 months of therapy (T12). During each visit, body composition was analyzed by phase-sensitive bio-impedance, and NAFLD was diagnosed and staged by Ultrasound (US) imaging. Surrogate biomarkers of NAFLD were also calculated and followed over time. Results. A significant decrease in anthropometric and glucometabolic parameters, insulin resistance, liver enzymes, and laboratory indices of hepatic steatosis was observed during treatment. Similarly, fat mass and visceral adipose tissue (VAT) decreased over time more than skeletal muscle and free-fat mass. US-assessed VAT thickness and the 12-point steatosis score also declined at T3 up to T12. Liver steatosis improved in most patients (70%), showing a reduction by at least one class in the semiquantitative US staging. Conclusion. Besides glucose control and body composition improvements, Semaglutide was effective in ameliorating the clinical appearance and severity of NAFLD in T2D patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures








Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Data are very limited for the highest dose of Semaglutide (2.4 mg), as most studies have focused on the 1 mg dose. 8 , 9 , 10 , 11”
From Impact of Semaglutide on fat mass, lean mass and muscle function in patients with obesity: The SEMALEAN study (2026) · cites this paper as [10]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“GLP-1 RAs, particularly semaglutide, have been shown to reduce liver steatosis and improve markers of liver inflammation and fibrosis in patients with type 2 diabetes and metabolic dysfunction-associated steatotic liver disease.34, 35, 36”
From The expanding role of GLP-1 receptor agonists: a narrative review of current evidence and future directions (2025) · cites this paper as [36]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607141 · Cited by 6,900 · cited 1×
“Semaglutide is one of the most potent GLP-1 RAs, as demonstrated by its beneficial effects on glucose control [24,25], CV and renal protection [26,27], weight loss, and improving body composition [28].”
BackgroundEASL–EASD–EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease
(2016) · Journal of Hepatology · doi:10.1016/j.jhep.2015.11.004 · Cited by 4,836
MAFLD: a consensus-driven proposed nomenclature for metabolic associated fatty liver disease
Eslam, M., Sanyal, A. J., George, J., Sanyal, A., Neuschwander-Tetri, B., Tiribelli, C., Kleiner, D. E., Brunt, E., Bugianesi, E., Yki-Järvinen, H., et al. (2020) · Gastroenterology · doi:10.1053/j.gastro.2019.11.312 · Cited by 3,286 · cited 15×
“Abbreviations NAFLD NonAlcoholic Fatty Liver Disease T2D Type 2 Diabetes IR Insulin Resistance HDL High Density Lipoproteins NASH NonAlcoholic Steatohepatitis MAFLD Metabolic Associated Fatty Liver Disease CV Cardiovascular SMM Skeletal Muscle Mass VAT Visceral Adipose Tissue GLP-1 RAs Glucagon-Like Peptide-1 Receptor…”
BackgroundInfluentialBedogni, G., Bellentani, S., Miglioli, L., Masutti, F., Passalacqua, M., Castiglione, A., & Tiribelli, C. (2006) · BMC Gastroenterology · doi:10.1186/1471-230x-6-33 · Cited by 3,042 · cited 1×
“3) was highly indicative of liver steatosis [31].”
BackgroundRoberts, H. C., Denison, H. J., Martin, H. J., Patel, H. P., Syddall, H., Cooper, C., & Sayer, A. A. (2011) · Age and Ageing · doi:10.1093/ageing/afr051 · Cited by 3,001 · cited 1×
“The hand grip (HG) strength test was performed using a manual hydraulic dynamometer (Lafayette Instrument, Lafayette, IN, USA) to assess the muscle strength in both hands [33].”
MethodA Placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis
Newsome, P. N., Buchholtz, K., Cusi, K., Linder, M., Okanoue, T., Ratziu, V., Sanyal, A. J., Sejling, A.-S., & Harrison, S. A. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2028395 · Cited by 2,039 · cited 1×
“4 mg) for 72 consecutive weeks, showing promising effects on intrahepatic fat accumulation but without significant changes in terms of liver fibrosis compared to placebo [43].”
BackgroundGlobal epidemiology of NAFLD-related HCC: trends, predictions, risk factors and prevention
Huang, D. Q., El-Serag, H. B., & Loomba, R. (2021) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-020-00381-6 · Cited by 1,855
Hepatic steatosis index: A simple screening tool reflecting nonalcoholic fatty liver disease
Lee, J.-H., Kim, D., Kim, H. J., Lee, C.-H., Yang, J. I., Kim, W., Kim, Y. J., Yoon, J.-H., Cho, S.-H., Sung, M.-W., et al. (2010) · Digestive and Liver Disease · doi:10.1016/j.dld.2009.08.002 · Cited by 1,621 · cited 1×
“A value over 36 was indicative of NAFLD and a value lower than 30 should exclude it [30].”
BackgroundHamaguchi, M., Kojima, T., Itoh, Y., Harano, Y., Fujii, K., Nakajima, T., Kato, T., Takeda, N., Okuda, J., Ida, K., et al. (2007) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2007.01526.x · Cited by 906 · cited 1×
“Moreover, in order to observe minimal variations in steatosis during treatment, the Hamaguchi 6-point score [36] was modified to obtain a more detailed ultrasound liver steatosis score (US-LSS), ranging from 0 to 12 points (Table 1).”
MethodThe Role of Insulin Resistance in Nonalcoholic Fatty Liver Disease
Utzschneider, K. M., & Kahn, S. E. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-0587 · Cited by 856 · cited 1×
“Insulin resistance induces an imbalance between lipid production and disposal, leading to lipid accumulation in hepatocytes, chronic low-grade inflammation, progression to NASH, and adverse hepatic and extrahepatic outcomes [11].”
Background2019 Global NAFLD Prevalence: A Systematic Review and Meta-analysis
Le, M. H., Yeo, Y. H., Li, X., Li, J., Zou, B., Wu, Y., Ye, Q., Huang, D. Q., Zhao, C., Zhang, J., et al. (2022) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2021.12.002 · Cited by 711
Current and future pharmacological therapies for NAFLD/NASH
Sumida, Y., & Yoneda, M. (2018) · Journal of Gastroenterology · doi:10.1007/s00535-017-1415-1 · Cited by 667 · cited 1×
“On the other hand, antifibrotic treatments should only be considered in patients with moderate-to-severe NASH, or those at high risk of disease progression [21].”
BackgroundNAFLD as a Continuum: From Obesity to Metabolic Syndrome and Diabetes
Godoy-Matos, A. F., Silva Júnior, W. S., & Valerio, C. M. (2020) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-020-00570-y · Cited by 643 · cited 1×
“Its prevalence rises to more than 70% among individuals with metabolic disorders such as metabolic syndrome, type 2 diabetes (T2D), and obesity [2,3].”
BackgroundModulation of Insulin Resistance in Nonalcoholic Fatty Liver Disease
Khan, R. S., Bril, F., Cusi, K., & Newsome, P. N. (2019) · Hepatology · doi:10.1002/hep.30429 · Cited by 542 · cited 1×
“GLP-1 RAs appear to have the most promising therapeutic role in NAFLD [22,23], although the indications provided so far are unclear.”
BackgroundComparison of MAFLD and NAFLD diagnostic criteria in real world
Lin, S., Huang, J., Wang, M., Kumar, R., Liu, Y., Liu, S., Wu, Y., Wang, X., & Zhu, Y. (2020) · Liver International · doi:10.1111/liv.14548 · Cited by 516 · cited 1×
“Compared to NAFLD, MAFLD seems to be associated with a higher risk of disease progression, and so should be recognized and treated early to avoid harmful consequences over time [14].”
BackgroundEpidemiology of non-alcoholic and alcoholic fatty liver diseases
Mitra, S., De, A., & Chowdhury, A. (2020) · Translational Gastroenterology and Hepatology · doi:10.21037/tgh.2019.09.08 · Cited by 513 · cited 1×
“NAFLD is the result of a metabolic disorder related to a sedentary lifestyle, excessive calorie intake, insulin resistance (IR) [4], as well as genetic and environmental factors [5].”
BackgroundUltrasound-based techniques for the diagnosis of liver steatosis
Ferraioli, G., & Monteiro, L. B. S. (2019) · World Journal of Gastroenterology · doi:10.3748/wjg.v25.i40.6053 · Cited by 506 · cited 2×
“severity of fat infiltration in the liver [35].”
BackgroundMethodEmerging therapeutic approaches for the treatment of NAFLD and type 2 diabetes mellitus
Ferguson, D., & Finck, B. N. (2021) · Nature Reviews Endocrinology · doi:10.1038/s41574-021-00507-z · Cited by 504 · cited 3×
“GLP-1 RAs appear to have the most promising therapeutic role in NAFLD [22,23], although the indications provided so far are unclear.”
BackgroundGlucagon-like peptide 1 decreases lipotoxicity in non-alcoholic steatohepatitis
Armstrong, M. J., Hull, D., Guo, K., Barton, D., Hazlehurst, J. M., Gathercole, L. L., Nasiri, M., Yu, J., Gough, S. C., Newsome, P. N., et al. (2016) · Journal of Hepatology · doi:10.1016/j.jhep.2015.08.038 · Cited by 456 · cited 1×
“In particular, they reduce de novo lipogenesis, enhance the mitochondrial beta-oxidation of free fatty acids, reduce systemic, adipose, and hepatic insulin resistance, and increase the clearance of very low-density lipoproteins [37].”
BackgroundCapehorn, M. S., Catarig, A.-M., Furberg, J. K., Janez, A., Price, H. C., Tadayon, S., Vergès, B., & Marre, M. (2020) · Diabetes & Metabolism · doi:10.1016/j.diabet.2019.101117 · Cited by 412 · cited 1×
“Semaglutide is one of the most potent GLP-1 RAs, as demonstrated by its beneficial effects on glucose control [24,25], CV and renal protection [26,27], weight loss, and improving body composition [28].”
BackgroundAroda, V. R., Ahmann, A., Cariou, B., Chow, F., Davies, M. J., Jódar, E., Mehta, R., Woo, V., & Lingvay, I. (2019) · Diabetes & Metabolism · doi:10.1016/j.diabet.2018.12.001 · Cited by 296 · cited 1×
“Semaglutide is one of the most potent GLP-1 RAs, as demonstrated by its beneficial effects on glucose control [24,25], CV and renal protection [26,27], weight loss, and improving body composition [28].”
BackgroundHigh-density lipoproteins, reverse cholesterol transport and atherogenesis
Pownall, H. J., Rosales, C., Gillard, B. K., & Gotto, A. M. (2021) · Nature Reviews Cardiology · doi:10.1038/s41569-021-00538-z · Cited by 246 · cited 1×
“Low HDL cholesterol is classically considered a CV risk factor, showing a crucial role of HDL in sustaining reverse cholesterol transport, reducing cholesterol accumulation in the vascular wall, smothering intimal inflammation, and lastly preventing or halting atherosclerosis [41].”
BackgroundBosy-Westphal, A., Jensen, B., Braun, W., Pourhassan, M., Gallagher, D., & Müller, M. J. (2017) · European Journal of Clinical Nutrition · doi:10.1038/ejcn.2017.27 · Cited by 231 · cited 7×
“Abbreviations NAFLD NonAlcoholic Fatty Liver Disease T2D Type 2 Diabetes IR Insulin Resistance HDL High Density Lipoproteins NASH NonAlcoholic Steatohepatitis MAFLD Metabolic Associated Fatty Liver Disease CV Cardiovascular SMM Skeletal Muscle Mass VAT Visceral Adipose Tissue GLP-1 RAs Glucagon-Like Peptide-1 Receptor…”
MethodInfluentialFlint, A., Andersen, G., Hockings, P., Johansson, L., Morsing, A., Sundby Palle, M., Vogl, T., Loomba, R., & Plum‐Mörschel, L. (2021) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.16608 · Cited by 224 · cited 1×
“Similarly, satisfactory effects on liver steatosis but not liver stiffness were confirmed in a study using magnetic resonance imaging to assess changes in liver parenchyma [44].”
BackgroundHusain, M., Bain, S. C., Jeppesen, O. K., Lingvay, I., Sørrig, R., Treppendahl, M. B., & Vilsbøll, T. (2020) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13955 · Cited by 209
Newsome, P., Francque, S., Harrison, S., Ratziu, V., Van Gaal, L., Calanna, S., Hansen, M., Linder, M., & Sanyal, A. (2019) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.15316 · Cited by 186 · cited 2×
“In line with our results, two large clinical trials, in which NAFLD was an established comorbidity among the enrolled patients, have recently shown a dose-dependent reduction of serum ALT and high-sensitivity C-reactive protein values after treatment with Semaglutide [38].”
BackgroundResultHistory of Nonalcoholic Fatty Liver Disease
Lonardo, A., Leoni, S., Alswat, K., & Fouad, Y. M. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21165888 · Cited by 170 · cited 1×
“Its prevalence rises to more than 70% among individuals with metabolic disorders such as metabolic syndrome, type 2 diabetes (T2D), and obesity [2,3].”
BackgroundNonalcoholic fatty liver disease: A main driver of insulin resistance or a dangerous liaison?
Gruben, N., Shiri‐Sverdlov, R., Koonen, D. P. Y., & Hofker, M. H. (2014) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2014.08.004 · Cited by 167
Role of diet and lifestyle changes in nonalcoholic fatty liver disease.
Nseir, W., Hellou, E., & Assy, N. (2014) · PubMed · doi:10.3748/wjg.v20.i28.9338 · Cited by 139 · cited 1×
“A healthy diet, lifestyle changes, and physical activity are the first-line therapy of NAFLD, demonstrated to improve IR, reduce systemic inflammation, promote weight loss, reduce fat accumulation, increase SMM, and, lastly, prevent negative outcomes [20].”
BackgroundDiagnosis and management of non-alcoholic fatty liver disease
Jennison, E., Patel, J., Scorletti, E., & Byrne, C. D. (2019) · Postgraduate Medical Journal · doi:10.1136/postgradmedj-2018-136316 · Cited by 135 · cited 1×
“Noninvasive imaging techniques, such as US, and laboratory surrogate biomarkers of liver steatosis have been validated to diagnose NAFLD [40].”
MethodSonographic Assessment of Regional Adiposity
Vlachos, I. S., Hatziioannou, A., Perelas, A., & Perrea, D. N. (2007) · American Journal of Roentgenology · doi:10.2214/ajr.07.2366 · Cited by 102 · cited 2×
“Using the same method, the distance between the outer line of the recti muscle and the skin surface was considered as the thickness of the subcutaneous adipose tissue [34].”
MethodShida, T., Akiyama, K., Oh, S., Sawai, A., Isobe, T., Okamoto, Y., Ishige, K., Mizokami, Y., Yamagata, K., Onizawa, K., et al. (2017) · Journal of Gastroenterology · doi:10.1007/s00535-017-1377-3 · Cited by 93 · cited 1×
“With particular reference to this point, it should be emphasized that the simultaneous loss of SMM and accumulation of visceral adipose tissue (VAT), the so-named sarcopenic visceral obesity, is associated with higher levels of IR and metabolic impairment, increasing the risk of NAFLD [18,19].”
BackgroundPinyopornpanish, K., Leerapun, A., Pinyopornpanish, K., & Chattipakorn, N. (2021) · Gut and Liver · doi:10.5009/gnl20367 · Cited by 81 · cited 1×
“Although metformin has shown anti-inflammatory properties and potentially positive effects on hepatic steatosis and steatohepatitis, by suppressing de novo lipogenesis, enhancing fatty acid oxidation, and promoting degradation of intracellular lipids that accumulate in hepatocytes [22,42] no significant improvement in…”
BackgroundQuek, J., Ng, C. H., Tang, A. S. P., Chew, N., Chan, M. Y., Khoo, C. M., Wei, C. P., Chin, Y. H., Tay, P. W. L., Lim, G., et al. (2022) · Endocrine Practice · doi:10.1016/j.eprac.2022.03.016 · Cited by 80
NAFLD Preclinical Models: More than a Handful, Less of a Concern?
Oligschlaeger, Y., & Shiri‐Sverdlov, R. (2020) · Biomedicines · doi:10.3390/biomedicines8020028 · Cited by 74
De Matteis, C., Cariello, M., Graziano, G., Battaglia, S., Suppressa, P., Piazzolla, G., Sabbà, C., & Moschetta, A. (2021) · Scientific Reports · doi:10.1038/s41598-021-94277-3 · Cited by 71
Self-citationVolpe, S., Lisco, G., Racaniello, D., Fanelli, M., Colaianni, V., Vozza, A., Triggiani, V., Sabbà, C., Tortorella, C., De Pergola, G., et al. (2022) · Nutrients · doi:10.3390/nu14122414 · Cited by 67 · cited 3×
“, KG, Hamburg, Germany), as described elsewhere [28].”
BackgroundResultSelf-citationDe Fré, C. H., De Fré, M. A., Kwanten, W. J., Op de Beeck, B. J., Van Gaal, L. F., & Francque, S. M. (2019) · Obesity Reviews · doi:10.1111/obr.12776 · Cited by 53
Marchesini, G., Roden, M., & Vettor, R. (2016) · Journal of Hepatology · doi:10.1016/j.jhep.2016.11.002 · Cited by 49
Sarcopenia is associated with non-alcoholic fatty liver disease in men with type 2 diabetes
Seo, D. H., Lee, Y.-H., Park, S. W., Choi, Y. J., Huh, B. W., Lee, E., Huh, K. B., Kim, S. H., & Cha, B.-S. (2020) · Diabetes & Metabolism · doi:10.1016/j.diabet.2019.10.004 · Cited by 38 · cited 1×
“Low skeletal muscle mass (SMM), clinically known as sarcopenia, is associated with a greater risk of NAFLD and fibrosis [17].”
BackgroundArai, T., Atsukawa, M., Tsubota, A., Ono, H., Kawano, T., Yoshida, Y., Okubo, T., Hayama, K., Nakagawa‐Iwashita, A., Itokawa, N., et al. (2022) · JGH Open · doi:10.1002/jgh3.12780 · Cited by 34 · cited 1×
“Finally, a very recent pilot study tested the oral formulation of Semaglutide for 24 weeks in 16 TD2 patients with NAFLD, showing results consistent with our findings [45].”
ResultZhao, Y., Jia, M., Zhang, C., Feng, X., Chen, J., Li, Q., Zhang, Y., Xu, W., Dong, Y., Jiang, Y., et al. (2022) · Scientific Reports · doi:10.1038/s41598-022-06879-0 · Cited by 30
Shi, Y., Chen, X., Qiu, H.-N., Jiang, W.-R., Zhang, M., Huang, Y., Ji, Y.-P., Zhang, S., Li, C., & Lin, J. (2021) · Scandinavian Journal of Gastroenterology · doi:10.1080/00365521.2021.1879244 · Cited by 22 · cited 1×
“With particular reference to this point, it should be emphasized that the simultaneous loss of SMM and accumulation of visceral adipose tissue (VAT), the so-named sarcopenic visceral obesity, is associated with higher levels of IR and metabolic impairment, increasing the risk of NAFLD [18,19].”
BackgroundNucci, S. D., Castellana, F., Zupo, R., Lampignano, L., Chito, M. D., Rinaldi, R., Giannuzzi, V., Cozzolongo, R., Piazzolla, G., Giannelli, G., et al. (2022) · Frontiers in Nutrition · doi:10.3389/fnut.2022.1002669 · Cited by 19
Self-citationZupo, R., Castellana, F., Panza, F., Castellana, M., Lampignano, L., Cincione, R. I., Triggiani, V., Giannelli, G., Dibello, V., Sardone, R., et al. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10081695 · Cited by 17
Self-citationPergola, G. D., Castellana, F., Zupo, R., Nucci, S. D., Panza, F., Castellana, M., Lampignano, L., Chito, M. D., Triggiani, V., Sardone, R., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-03583-3 · Cited by 11
Self-citationEffectiveness and clinical benefits of new anti-diabetic drugs: A real life experience
Piazzolla, G., Vozza, A., Volpe, S., Bergamasco, A., Triggiani, V., Lisco, G., Falconieri, M., Tortorella, C., Solfrizzi, V., & Sabbà, C. (2022) · Open Medicine · doi:10.1515/med-2022-0504 · Cited by 10 · cited 1×
“Moreover, GLP-1 RAs reduce intrahepatic fat accumulation and hepatic cytolysis, also reducing tissue inflammation [38,39].”
BackgroundSelf-citation
Cited by
Moiz, A., Filion, K. B., Tsoukas, M. A., Yu, O. H. Y., Peters, T. M., & Eisenberg, M. J. (2025) · EClinicalMedicine · doi:10.1016/j.eclinm.2025.103363 · Cited by 157
“36 In the recent ESSENCE trial, 62.9% of patients receiving semaglutide achieved resolution of metabolic dysfunction-associated steatohepatitis without worsening of fibrosis at 72 weeks, compared to 34.3% in the placebo group (estimated treatment difference [ETD]: 28.7%, 95% CI 21.1, 36.2).”
InfluentialLocatelli, J. C., Costa, J. G., Haynes, A., Naylor, L. H., Fegan, P. G., Yeap, B. B., & Green, D. J. (2024) · Diabetes Care · doi:10.2337/dci23-0100 · Cited by 152
Semaglutide and cancer: A systematic review and meta-analysis
Nagendra, L., BG, H., Sharma, M., & Dutta, D. (2023) · Diabetes & Metabolic Syndrome: Clinical Research & Reviews · doi:10.1016/j.dsx.2023.102834 · Cited by 86
Bandyopadhyay, S., Das, S., Samajdar, S. S., & Joshi, S. R. (2023) · Diabetes & Metabolic Syndrome: Clinical Research & Reviews · doi:10.1016/j.dsx.2023.102849 · Cited by 64
Volpe, S., Lisco, G., Fanelli, M., Racaniello, D., Colaianni, V., Lavarra, V., Triggiani, D., Crudele, L., Triggiani, V., Sabbà, C., et al. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1240263 · Cited by 73
Self-citation
Metadata
- Authors
- Volpe, S., Lisco, G., Fanelli, M., Racaniello, D., Colaianni, V., Triggiani, D., Donghia, R., Crudele, L., Rinaldi, R., Sabbà, C., Triggiani, V., De Pergola, G., & Piazzolla, G.
- Affiliations
- University of Bari Aldo Moro (IT)
- Gastroenterology Hospital "Saverio de Bellis" (IT)
- National Institute of Gastroenterology IRCCS “S. de Bellis”, Research Hospital, Castellana Grotte, Via Turi 27, 70013 Bari, Italy
- Corresponding author
- Piazzolla, Giuseppina
- ORCID
- Venue
- Nutrients
- Publisher
- MDPI AG
- Published
- 2022-11-04
- Volume
- 14
- Issue
- 21
- Pages
- 4673
- ISSN
- 2072-6643 (ISSN-L)
- PMC
- PMC9657108
- OpenAlex
- W4308720508
- Cited by
- 84
- References
- 46
- Citations by year
- 2026: 16 · 2025: 23 · 2024: 27 · 2023: 18
- FWCI
- 12.27
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Nutrients (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- CINECA IRIS Institutional Research Information System (University of Bari Aldo Moro) (submittedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- semaglutide, non-alcoholic fatty liver disease, type 2 diabetes, GLP-1 receptor agonists, hepatic steatosis, visceral adipose tissue, body composition, insulin resistance, metformin add-on therapy, real-world effectiveness
- MeSH terms
- Semaglutide, Diabetes Mellitus, Type 2, Glucagon-Like Peptides, Humans, Prospective Studies, Non-alcoholic Fatty Liver Disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.